Details of the Drug Reposition

General Information of This Drug (ID: DMXYLQ3)

Drug Name
Lansoprazole   DMXYLQ3
Synonyms
Lancid; Lanproton; Lansopep; Lansoprazol; Lansoprazol [INN-Spanish]; Lansoprazole [USAN:BAN:INN]; Lansoprazolum; Lansoprazolum [INN-Latin]; Lansox; Lanston; Lanzol-30; Lanzopral; Lanzor; Lasoprol; Limpidex; Mesactol; Monolitum; Ogastro; Opiren; Agopton; Aprazol; Bamalite; Blason; Compraz; Ilsatec; Ketian; Prevacid; Prevacid 24HR; Prevacid Iv; Prevacid NapraPAC; Prevacid SoluTab; Prezal; Pro Ulco; Prosogan; Suprecid; Takepron; Zoprol; lansoprazole; 103577-45-3; A-65006; AG 1749; AG-1749; CHEBI:6375; Dakar; HSDB 7204; Lanz; Lanzo; Ogast; Promp; Ulpax; Zoton
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastrinoma DIS4IMNF 2C10.1 Approved [1]
Gastric ulcer DISBBGVO DA60 Approved [1]
Peptic ulcer DISL8XZI DA61 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Eosinophilic esophagitis DISR8WSB DA24.1 Discontinued in Phase 3 [2]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Duodenal ulcer DISNHHCN DA63 Discontinued in Phase 2 [3]
Constipation DISRQXWI DD91.1 Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastroesophageal reflux disease DISQ8G5S DA22.Z Discontinued in Phase 1 [5]
Erosive esophagitis DIST4BF8 DA25.0 Discontinued in Phase 1 [6]
------------------------------------------------------------------------------------

References

1 Lansoprazole FDA Label
2 Minimally Invasive Surgical Therapy for BPH
3 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
4 Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria
5 Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
6 Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer